Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplement Figure.1.

Published byBernice Sims Modified over 5 years ago

Similar presentations

Presentation on theme: "Supplement Figure.1."— Presentation transcript:

1 Supplement Figure.1

2 Supplement Figure.2 Heregulin high Heregulin low HARA A549 QG56 PC3
Patritumab 100ug/ml pERK ERK β-actin

3 Supplement Figure.3 B. A549 + + - - - + - + siMock siHRG Patritumab
pERK ERK Heregulin A549 Patritumab - 　 + - 　 + siMock siHRG pHER3 pAKT HER3 AKT - 　 - + 　 + β-actin

4 Supplement Figure.4 33% inhibition Mean Pixel Density 44% inhibition

5 Supplement Figure.5 PC9Mock treated with erlotinib
PC9HRG treated with erlotinib Ratio of expression Time (hours)

6 Supplement Figure.6 PC9HRG treated with erlotinib
PC9HRG treated with erlotinib plus pertuzumab Ratio of expression Ratio of expression Time (hours) Time (hours)

7 Supplement Figure.7 PC9HRG treated with control
PC9HRG treated with patritumab Ratio of expression Ratio of expression Time (hours) Time (hours) PC9HRG treated with erlotinib plus patritumab PC9HRG treated with erlotinib Ratio of expression Ratio of expression Time (hours) Time (hours)

8 - + Supplement Figure.8 HCC827 （EGFR mutant） Patritumab 100ug/ml pHER3
Patritumab 100ug/ml pHER3 HER3 pAKT AKT

9

10

Download ppt "Supplement Figure.1."

Similar presentations

Cell number (% vehicle control) cisplatin concentration (µM)gefitinib concentration (µM) 10 1 10 2 10 3 cell number expression level (fluorescence intensity)

Cell number (% vehicle control) cisplatin concentration (µM)gefitinib concentration (µM) cell number expression level (fluorescence intensity)
P-ERK Total ERK Mel888 CHL1 WM793 0 10 50 BRAFi (nmol/L) Supplemental Figure 2: Other surface molecules unaffected ns PD-L1 ns MCSP DMSO BRAFi Supplemental.

P-ERK Total ERK Mel888 CHL1 WM BRAFi (nmol/L) Supplemental Figure 2: Other surface molecules unaffected ns PD-L1 ns MCSP DMSO BRAFi Supplemental.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
NPV-BEZ235PKI-587 GDC-0980PD0325901 Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD0325901.

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.

Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
Supplemental Figure S2. Location and H 2 O 2 -dependent binding of RBPs to biotinylated MKP-1 transcripts. (A) Schematic of the MKP-1 mRNA showing the.

Supplemental Figure S2. Location and H 2 O 2 -dependent binding of RBPs to biotinylated MKP-1 transcripts. (A) Schematic of the MKP-1 mRNA showing the.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.
Fig. S1 1 Oxygen consumption rate (pmol/sec/10⁶cells) shLKB1#1 control * untreated 25 μM erlotinib H358 Vector LKB1 Oxygen consumption rate (pmol/sec/10⁶cells)

Fig. S1 1 Oxygen consumption rate (pmol/sec/10⁶cells) shLKB1#1 control * untreated 25 μM erlotinib H358 Vector LKB1 Oxygen consumption rate (pmol/sec/10⁶cells)
Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Supplementary Figure S1 a

Supplementary Figure S1 a
PLUS.

PLUS.
The mTOR/AKT Inhibitor Temsirolimus Prevents Deep Infiltrating Endometriosis in Mice  Mahaut Leconte, Carole Nicco, Charlotte Ngô, Christiane Chéreau,

The mTOR/AKT Inhibitor Temsirolimus Prevents Deep Infiltrating Endometriosis in Mice  Mahaut Leconte, Carole Nicco, Charlotte Ngô, Christiane Chéreau,
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Supplementary figures

Supplementary figures
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

Similar presentations

Ads by Google